Recent News

An advanced, non-invasive test, Trucheck is capable of identifying over 70 solid tumors 

Dubai: In an effort to support preventive cancer care, Burjeel Hospitals, has announced the launch of Trucheck™ intelli, an advanced, non-invasive testing method for the early detection of cancer. A breakthrough in integrative diagnostic technology and personalized care, Trucheck requires just a simple blood test and is capable of identifying more than 70 solid tumors.  

A Simple Method Offering Precise, Personalized Care 

Globally, the cancer burden continues to grow, putting tremendous physical, financial, and emotional strains on individuals and families. According to the World Health Organization (WHO), cancer is the second leading cause of death globally. However, the survival rate can be improved through early detection and advanced care. Trucheck plays a vital role in achieving this.   

By introducing Trucheck at Burjeel Hospitals, Burjeel Cancer Institute (BCI) is taking the lead in preventive cancer care. This cutting-edge test is designed to detect circulating tumor cells (CTCs) and molecular signatures indicative of cancer. With its advanced diagnostic capabilities, Trucheck enables early cancer detection, often before symptoms arise, setting a new standard in non-invasive, preventive healthcare.  

“Trucheck has shown an exceptional accuracy rate exceeding 95% in detecting more than 70 types of cancers such as breast, lung, pancreatic, liver, thyroid, and gastrointestinal cancers. Unlike tests that depend mainly on circulating tumor DNA (ctDNA) methylation patterns, Trucheck emphasizes intact tumor cells as its biomarker. The rationale is that CTCs might give a more direct signal of malignancy and provide more morphological and protein-level information,” explained Prof. Humaid Al Shamsi, CEO, Burjeel Cancer Institute (BCI), who has contributed to the research behind Trucheck. With rapid result turnaround, the test helps clinicians make timely and personalized treatment decisions.  

Preventive Screening for Adults Aged 40 and Above 

Unlike traditional testing methods, Trucheck doesn’t require fasting or preparation. Asymptomatic individuals aged 40 and above can benefit from this method, which serves as a valuable preventive tool for the general population, high-risk individuals with genetic or family histories, and patients under post-treatment surveillance. It provides highly accurate, research-backed results with minimal false positives or negatives. One can opt for this test once a year to ensure a cancer-free life. 

“In cancer care, early diagnosis is the cornerstone. It makes a huge difference. By introducing Trucheck, we are bringing unprecedented precision and accessibility to preventive cancer care. Giving access to early diagnosis can save lives while reducing the social and economic burden of cancer,” added Dr. Humaid. 

Catching cancer early can make the journey more manageable. It opens the door to more treatment options, better outcomes, and a greater chance of recovery. With its ability to detect cancer at its earliest stages, Trucheck has the potential to transform the way cancer is diagnosed, treated, and managed.  

Burjeel Medical City was honored in the ‘Large Facility’ category, and six Emirati employees of the Group received individual awards for their excellence in medical, administrative, healthcare, and leadership roles 

Abu Dhabi: Burjeel Holdings, a leading super-specialty healthcare services provider in MENA, has once again excelled at the Nafis Award, a recognition of its commitment to empowering Emirati professionals and building sustainable career pathways in healthcare. This year, the Group received seven awards in ‘Large Facility’ and ‘Individual’ categories for its ongoing efforts to attract, develop, and retain UAE Nationals across its facilities.  

The Nafis Award, an initiative launched as part of the ‘Projects of the 50’ agenda, aims to enhance the competitiveness of Emirati human resources and empower them to occupy jobs in the private sector. The award was launched under the patronage and guidance of His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister, Minister of the Presidential Court, Chairman of the Emirati Talent Competitiveness Council. The winners were announced during the third cycle of the award ceremony held in Abu Dhabi.  

While Burjeel Medical City (BMC) won first place in the ‘Large Facility’ category, six Emirati employees received individual awards for their excellence in medical, administrative, healthcare, and leadership roles. Dr. Naser Alriyami, CEO of Al Dhafra Region, Burjeel Holdings, and Dr. Mohamed Almarzooqi, Medical Director & Consultant Interventional Radiology, Burjeel Hospital, Abu Dhabi, won first and second place in the ‘Leadership’ category, respectively. In the ‘Healthcare’ category, Sara Alkatheeri and Fatma Ben Ammar, Nutritionists at BMC, won first and third place, respectively. Dr. Mohamed Muath ADI, Head of Department & Consultant Orthopedic Surgeon, BMC, received second place in the ‘Medical’ category, while Alya Almazrouei, Manager, Outreach and Stakeholder Engagement, Burjeel Holdings, won second place in the ‘Administrative’ category.  

“We are honored to receive these awards that recognize our ongoing efforts to invest in Emirati talent and strengthen their contributions to the private healthcare sector. We are proud to see them leading transformation across our facilities, contributing meaningfully at every level. Their growth reflects our deep-rooted commitment to building a future-ready healthcare workforce shaped by local talent,” said Dr. Shamsheer Vayalil, Founder and Chairman, about the achievement.  

Over the years, Burjeel Holdings has steadily increased the number of UAE Nationals across its facilities, investing in structured training, mentorship, and development programs. 

 Dr. Tahani Al Qadri, Group Director of Emiratization and Academics at Burjeel Holdings, said, “Our Emirati colleagues play an essential role in shaping the future of healthcare in the UAE. At Burjeel Holdings, we are actively building pathways for Emirati talent to thrive across a range of roles, including leadership. Through targeted programs, mentorship, and strategic partnerships like Nafis, we’re integrating local talent into every layer of our healthcare ecosystem and equipping them with the skills and experiences needed for long-term success.” 

Over the past two years, Burjeel Holdings saw a 300% increase in the number of UAE Nationals across its units, with nearly 30% now serving in senior roles. Its initiatives continue to inspire more young Emiratis to pursue meaningful careers in healthcare.  

Breast cancer treatment is often a journey filled with complex decisions. A 51-year-old woman, previously treated for breast cancer, presented with a new challenge—an ulcerative lesion in the nipple-areola complex (NAC). Initially misdiagnosed as triple-negative breast cancer, further evaluation at Burjeel Breast Center revealed Paget’s disease with ductal carcinoma in situ (DCIS). 

Accurate Diagnosis 

Expert review by Burjeel’s pathology team prevented unnecessary chemotherapy. This highlights the importance of second opinions and precise pathology in cancer care. 

Surgical Management 

The patient required excision of the entire NAC and surrounding ulcerated skin (8 × 6 cm). Wishing to preserve her implant-based reconstruction, she declined invasive options such as latissimus dorsi flap. The surgical team recommended a Medial Intercostal Artery Perforator (MICAP) flap with skin paddle, a muscle-sparing technique ideal for such complex cases. 

The Procedure 

Surgeons successfully performed a wide local excision followed by immediate partial breast reconstruction. The MICAP flap allowed skin resurfacing while preserving the implant. The patient recovered smoothly, with excellent cosmetic and functional results. 

Outcome and Follow-up 

Final histology confirmed Paget’s disease with DCIS—completely excised with clear margins and no invasive carcinoma. Multidisciplinary review concluded the surgery was curative, eliminating the need for further treatment. 

Conclusion 

This case underscores Burjeel Cancer Institute’s expertise in delivering personalized, minimally invasive breast reconstruction solutions, helping women regain both health and confidence after cancer surgery. 

Our Experts

Dr. Hazem Khout

Consultant Breast Oncoplastic Surgeon, Burjeel Cancer Institute 

View Profile

Dr. Omar Layth Qassid

Consultant Anatomic Pathology, Burjeel Medical City

View Profile

Dr. Lakshmanarajan Karuppasamy Mariyamma

Specialist Anesthesia, Burjeel Medical City 

View Profile

Breakthrough findings offer hope to over 500 million people living with diabetes and new solutions in remote healthcare.

NEW YORK, September 26, 2025 – Axiom Space and Burjeel Holdings released the preliminary results of the “Suite Ride” research conducted during the Axiom Mission 4 (Ax-4). The research concluded that everyday diabetes tools used by millions on Earth can be used comprehensively to provide end-to-end diabetes monitoring from space to ground and back to space—a breakthrough in opening the door to future astronauts with diabetes and providing new solutions in remote healthcare.

The results were revealed at a ceremony held at Burjeel Institute for Global Health, New York, in the presence of global space and healthcare experts, and teams from Axiom Space and Burjeel Holdings. Building on these findings, the healthcare group also announced its ambition of working toward sending the first astronaut with diabetes into space.

Axiom Space and Burjeel Holdings teamed up on the research program during the Ax-4 mission aboard the International Space Station this summer. Sending up a suite of remote care capabilities, the Suite Ride initiative explored how to manage diabetes in space, marking a meaningful step toward making spaceflight accessible for those with historically disqualifying conditions.

The research results found that continuous glucose monitors (CGMs) and insulin pens can operate reliably in the extreme conditions of space. Early results suggest that CGM devices can perform with accuracy comparable to Earth-based readings, enabling real-time glucose monitoring of astronauts in microgravity and can communicate readings to the ground. Insulin pens flown on the space station are now undergoing post-flight testing to evaluate the integrity of the formulation. This continues research from Virgin Galactic’s Galactic 07 mission where a successful technical demonstration was conducted confirming that commercially available insulin pens can dispense accurate doses in microgravity, aligning with International Organization for Standardization (ISO) guidelines.

“This is about inspiring people everywhere,” said Gavin D’Elia, Global Head of Pharma, Axiom Space. “A diagnosis shouldn't end your dream of space exploration. Together, we’re advancing the potential to fly the first astronaut with diabetes and to unlock innovation in healthcare.”

The Suite Ride initiative delivered several historic firsts:

• First continuous glucose monitoring of crew aboard the space station
• First insulin pens ever flown to station
• First validation of glucose monitoring across multiple measurement methods on the space station

Beyond the benefits to space exploration, the research findings extend to advancing remote and underserved communities worldwide. “Burjeel Holdings initiated this study to pioneer space medicine in line with the UAE’s space ambitions. Besides opening the door for astronauts with diabetes, these findings will also transform the way we deliver care here on Earth. From 250 miles above Earth to 25 miles offshore on oil rigs, we are advancing new models of remote care,” said Dr. Mohammad Fityan, Chief Medical Officer at Burjeel Medical City and Clinical Lead of the Burjeel–Ax-4 Space Health Research.

The research builds on a long tradition of space-driven medical innovation. In the 1970s, a miniaturized pump designed for the Viking Mars lander was adapted into the world’s first wearable insulin pump and used by millions of patients. The Suite Ride initiative represents the next chapter in this legacy, opening space to populations previously excluded and advancing real-time medical monitoring for extreme environments on Earth and beyond.

Axiom Space and Burjeel Holdings will continue to work together to find innovative solutions in chronic disease management for use on and off the planet.

ABOUT AXIOM SPACE Axiom Space is building the world’s first commercial space station – Axiom Station. Serving as a cornerstone for sustained human presence in space, this next-generation orbital platform fosters groundbreaking innovation and research in microgravity, and cultivates the vibrant, global space economy of tomorrow. Today, driven by the vision of leading humanity's journey off planet, Axiom Space is the principal provider of commercial human spaceflight services to the International Space Station and developer of advanced spacesuits for the Moon and low-Earth orbit. Axiom Space is building era-defining space infrastructure that will empower our civilization to transcend Earth for the benefit of every human, everywhere. For more information about Axiom Space, visit www.axiomspace.com.

ABOUT BURJEEL HOLDINGS

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. Its network comprises 112 assets across the UAE, Oman, and Saudi Arabia, including 20 hospitals, 37 medical centers, 30 physiotherapy and wellness centers, 15 pharmacies, and 10 other allied services. Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia and Tajmeel.

Media Contacts: media@axiomspace.com

krish@burjeelholdings.com

The Burjeel by the Beach Clinic was inaugurated by H.E. Sheikh Zayed bin Saeed bin Zayed Al Nahyan and H.E. Sheikh Hamdan bin Saeed bin Zayed Al Nahyan  

Abu Dhabi, May 28: Burjeel Holdings, a leading provider of super-specialty healthcare services in the MENA region, has officially inaugurated the Burjeel by the Beach Clinic at Abu Dhabi’s Saadiyat Island, marking a significant step in its ongoing commitment to expanding access to premium healthcare across the UAE. Strategically located in the heart of Saadiyat Island, the center is designed to serve the diverse community of residents, expatriates, tourists, and corporate professionals. The new center was launched by H.E. Sheikh Zayed bin Saeed bin Zayed Al Nahyan and H.E. Sheikh Hamdan bin Saeed bin Zayed Al Nahyan. 

The launch event was attended by Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, Mr. Saif Alfalahi, Vice Chairman & Non-Executive Director – Independent, Burjeel Holdings, and Mr. Omran Al Khoori, Executive Director, Burjeel Holdings, along with members of Burjeel’s senior management.  

The center’s design embraces a ‘Burjeel by the Beach’ theme, creating a serene, coastal-inspired atmosphere that mirrors the tranquil surroundings of Saadiyat Island. This patient-centered approach ensures that the medical center provides expert care and a calming environment where individuals and families can prioritize their health and well-being. 

The facility offers a comprehensive range of services, including Family Medicine, Internal Medicine, Pediatrics, Obstetrics & Gynecology, and Psychiatry. In addition to its consulting doctors, the center will welcome visiting specialists from Burjeel’s broader network, ensuring continuous access to diverse medical expertise. For patients requiring more specialized interventions, the center will facilitate referrals to the Group’s flagship facility, Burjeel Medical City, for advanced care. 

The center has state-of-the-art diagnostic technologies, including X-ray and ultrasound imaging, providing patients with fast, accurate diagnostic assessments. A fully integrated in-house pharmacy further enhances the center’s ability to deliver seamless care, enabling patients to access diagnostics, consultations, and medications all in one convenient location. 

The center features six fully equipped consultation rooms, five specialized departments, and a dedicated treatment room. In addition, services such as phlebotomy for lab testing and on-site imaging ensure that patients receive a convenient and efficient care experience from start to finish. 

“The opening of Burjeel by the Beach Clinic at Saadiyat Island is a key milestone in our mission to bring world-class healthcare closer to our communities. We are proud to offer a facility that combines expert care with a welcoming environment, allowing individuals and families to focus on their health and well-being,” said Mr. John Sunil, Group CEO of Burjeel Holdings. 

The center will engage the community through wellness programs and corporate health partnerships, further nurturing preventive health practices and promoting the overall well-being of individuals, families, and businesses on the island. 

“We are dedicated to providing holistic healthcare that meets the diverse needs of our community. We focus on ensuring that every patient receives compassionate care that supports their physical and mental well-being in an environment that promotes healing and relaxation,” said Dr. Sonia Malik, Consultant, Family Medicine and Medical Director of Burjeel by the Beach Clinic, Saadiyat Island. 

The launch of Burjeel by the Beach Clinic at Saadiyat Island is part of Burjeel Holdings’ long-term healthcare expansion strategy, aimed at enhancing access to high-quality primary care while addressing the broad spectrum of healthcare needs in the community. 

Renowned orthopedic surgeon Prof. Dr. Munjed Al Muderis will offer cutting-edge osseointegration surgeries at the clinic 

Abu Dhabi | May 27, 2025: Ushering in a new era of prosthetic care in the UAE and across the region, Burjeel Medical City has launched the Al Muderis Osseointegration Clinic. The clinic is named after globally renowned orthopedic surgeon Prof. Dr. Munjed Al Muderis. As part of the Paley Middle East Clinic, the new center introduces to the region a groundbreaking surgical technique known as osseointegration, which anchors external prosthetic limbs directly to the bone, offering amputees enhanced mobility, stability, and comfort. 

The launch event was attended by Prof. Dr. Al Muderis, Dr. Dror Paley, founder of the Paley Middle East Clinic, and senior leadership from Burjeel Holdings, marking a significant milestone in making advanced amputee care more accessible to patients in the Middle East. 

At the heart of the clinic’s offering is the Osseointegrated Prosthetic Limb (OPL) system, which uses a titanium implant that integrates with the bone and extends through the skin to attach securely to an external prosthesis. This direct skeletal connection mimics natural limb movement and eliminates many limitations of conventional socket-based prosthetics. 

Unlike traditional prosthetic limbs, which can cause discomfort, skin issues, and joint complications, osseointegration enables a more intuitive, stable, and lifelike experience. The OPL not only improves balance and comfort but also allows for osseoperception, a phenomenon where users regain sensory feedback through the prosthetic. 

“Our goal has always been to restore mobility and dignity to amputees. By bringing this technology to the UAE, we’re building local capabilities and offering hope to those who have waited too long for the right kind of care,” said Prof. Dr. Al Muderis, who has treated more than 1,200 patients globally using this technology.  

The opening of the clinic marks a critical moment in the region’s healthcare evolution. The Middle East region is observed to have a comparatively higher prevalence of amputations, with a significant proportion resulting from trauma, particularly conflict-related and road-traffic injuries, which tend to impact younger age groups more. 

“The launch of the Al Muderis Osseointegration Clinic reinforces our commitment to bringing the world’s most advanced medical solutions to our communities. We envision this clinic not only as a center of excellence for patient care but also as a hub for knowledge transfer. Through surgeon training, research initiatives, and community outreach, we will extend this innovation across the UAE and beyond,” said Mr. John Sunil, Group CEO of Burjeel Holdings. 

Prof. Dr. Al Muderis, whose journey from fleeing Iraq as a refugee to becoming a globally respected surgeon has inspired many, emphasized the deeply personal mission behind the clinic. 

“Mobility is life,” he says. “Our mission is to ensure that limb loss never defines or limits a person’s future. Over the past decade, we pioneered the single-stage technique and enabled the technology for diabetic, vascular, pediatric, transtibial, and hip-disarticulation amputees. With this technology, we empower people with even the most complex injuries to reclaim their independence and quality of life.” 

Through expert second opinions, remote consultations, and visiting programs from leading global institutes, Burjeel Cancer Institute is set to transform the oncology landscape in the UAE 

Abu Dhabi, April 16, 2025: In a major step toward expanding access to world-class oncology services, Burjeel Cancer Institute (BCI), one of the largest cancer care networks in the UAE, has announced strategic collaborations with three globally renowned institutions — the European Institute of Oncology (IEO), the Children’s Hospital of Philadelphia (CHOP), and SJD Barcelona Children’s Hospital — during Abu Dhabi Global Healthcare Week. These partnerships aim to redefine oncology care in the region by advancing clinical services, research, education, and personalized oncology. 

BCI caters to over 5,000 patients each year and provides 360-degree tailored care, from diagnosis to survivorship programs. Its network is spread across the entire UAE, including key locations in Abu Dhabi, Al Ain, Dubai, Sharjah, and Al Dhafra, ensuring access to comprehensive and compassionate cancer care across all ages. 

These new collaborations will leverage teleconsultation and remote patient monitoring technologies, facilitate second opinions from international experts, and establish visiting programs to enable deeper knowledge exchange and enhance local capabilities. 

Enhancing Pediatric Cancer Care 

The Children’s Hospital of Philadelphia (CHOP) collaboration will enhance pediatric cancer care and strengthen capabilities in advanced diagnostics, remote consultations, and multidisciplinary second opinions. Visiting programs from CHOP will support knowledge exchange in subspecialized pediatric oncology. 

Mrs. Madeline Bell – President & Chief Executive Officer (CEO) for Children’s Hospital of Philadelphia (CHOP), said “We are excited to collaborate with BCI in advancing pediatric cancer care through shared expertise, remote care innovations, and training opportunities. Together, we will empower healthcare teams and support families facing childhood cancer.” 

The partnership with SJD Barcelona Children’s Hospital is set to further augment BCI’s capabilities in comprehensive childhood cancer care. The collaboration will offer continuous remote support and medical guidance, particularly for rare and complex pediatric cases. 

Dr. Manel del Castillo Rey – Chief Executive Officer (CEO) SJD Barcelona Children’s Hospital, commented, “Our collaboration with BCI provides a framework for sharing specialized knowledge and co-managing complex pediatric oncology cases. By bridging geographies, we can provide more children with access to expert care.” 

Integrating Global Expertise 

In partnership with the European Institute of Oncology (IEO), BCI will focus on strengthening cancer care in the UAE through clinical and scientific research development, training and education programs for healthcare professionals, and high-level clinical services. The collaboration will also support the creation of a distinguished network of visiting professors, capacity-building initiatives for nurses and pharmacists, and the establishment of a strategic advisory board for BCI. 

Ing. Mauro Melis – Chief Executive Officer IEO & Centro Cardiologico Monzino, said, “Our partnership with Burjeel Cancer Institute reflects a shared commitment to elevating standards in cancer care. Through collaborative research, clinical exchanges, and capacity-building, we aim to jointly accelerate innovation and improve outcomes for patients in the country and across the region.” 

Advancing Diagnostic Testing for Cancer 

In addition to these collaborations, Burjeel Cancer Institute also joined hands with AbbVie Biopharmaceuticals to advance a personalized medicine approach in cancer care. The collaboration aims to support the adoption and access to the latest testing techniques to enhance the diagnosis and treatment of patients with various types of cancer, including ovarian, lung, and colorectal malignancies. 

As part of this initiative, the anatomical pathology laboratory lead by Dr. Rawia Mubarak will introduce a test for the first time in the region for platinum-resistant ovarian cancer, which will help identify patients who may benefit from emerging targeted therapies—offering a more personalized path forward and renewed hope for better outcomes. 

Mr. Mohammad Aboubakr Abdulgawad Mohammad – General Manager for AbbVie Pharmaceuticals, said,“Through our collaboration with Burjeel Cancer Institute, we are proud to introduce this advanced test in the UAE, a critical step toward identifying individuals who may benefit from emerging targeted therapies. By adopting this innovation, physicians can offer a more personalized and effective approach to care.” 

Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute, remarked, “These global partnerships are a pivotal step in our mission to bring world-class cancer care to the region. By aligning with some of the most prestigious institutions worldwide, we are building a future-ready oncology ecosystem that prioritizes quality, access, and innovation for every patient we serve.” 

These partnerships underscore BCI’s strategic vision to not only expand its clinical capabilities but also serve as a regional hub for knowledge, innovation, and excellence in oncology. 

The strategic collaboration brings next-gen AI pathology tools to the region, enhancing diagnostic accuracy and access to advanced cancer care 

Abu Dhabi | New York, April 16, 2025: Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, has announced a strategic partnership with Paige, a US-based leader in next-generation AI technology. The collaboration aims to enhance access to advanced cancer diagnostics by deploying Paige’s AI-powered solutions across Burjeel’s healthcare network. It also seeks to address the global shortage of pathologists and accelerate access to rapid, reliable cancer diagnostics, particularly in underserved communities and emerging markets. The collaboration was announced during Abu Dhabi Global Health week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings.  

Paige has developed a suite of AI applications that support diagnostic decision making in cancer pathology. Paige Prostate Detect*, a key component of the suite, is the first FDA-approved AI algorithm, that works by detecting prostate cancer in core-needle biopsies. With this partnership, Burjeel Holdings will become one of the first in the region to offer these AI-powered diagnostic tools, reinforcing its commitment to delivering timely and accessible cancer care. Paige’s solutions are designed to augment the capabilities of pathologists, streamline workflows, and boost diagnostic confidence, ultimately resulting in better outcomes for patients. The partnership represents a significant step toward the democratization of advanced care, ensuring that even the most advanced technologies reach patients who need them most. 

“Our collaboration with Paige represents a transformative step in delivering cancer diagnostics across our network. By incorporating next-gen AI into our pathology services, we aim to enhance the speed and accuracy of cancer diagnosis, enabling more effective treatment decisions. This partnership also reflects our mission to bring world-class, technology-enabled care to emerging markets,” said John Sunil, Group CEO of Burjeel Holdings. 

Paige has earned multiple regulatory achievements in AI for pathology, including FDA Breakthrough Device Designation for Paige PanCancer Detect, Paige Breast Lymph Node, and Paige Prostate Detect. Burjeel Holdings will deploy these AI applications along with Paige OmniScreen, which simultaneously screens over 1,600 molecular biomarkers to support comprehensive cancer diagnosis and more personalized treatment. 

“Burjeel Holdings’ commitment to innovation and equitable care across the MENA region makes them a powerful ally in helping us close diagnostic gaps and bring the benefits of our AI technology to more patients, faster. This partnership helps deliver on our mission to make next-generation cancer diagnostics accessible worldwide and aligns with our vision to standardize access to cutting-edge diagnostics on a global scale,” said Peter Hamilton, General Manager of Diagnostics, Paige. 

The partnership marks a key milestone in positioning Burjeel Holdings as a regional hub for AI-enabled pathology, with the potential to scale this transformative technology across MENA and beyond.  

The agents speak over 15 widely used languages, including the Emirati dialect 

April 17 2025, Palo Alto/Abu Dhabi: In a significant leap towards establishing an integrated innovation ecosystem, Burjeel Holdings and US-based Hippocratic AI have announced a strategic partnership aimed at transforming healthcare delivery through safe, scalable, and empathetic AI at Abu Dhabi Global Health Week. What sets these agents apart is their ability to engage in natural, safety-focused, human-like conversations.  

Through the integration of Hippocratic AI’s multilingual, empathy-driven agents, Burjeel Holdings will deliver real-time, culturally aware support across a wide range of patient touchpoints, including appointment scheduling, patient education, health risk assessments, and follow-up check-ins. These advanced agents are capable of sustained, multi-turn dialogue, enabling them to provide consistent, compliant, and compassionate communication that enhances both the patient experience and care continuity.  

Hippocratic AI’s agents already speak over 15 widely used languages such as Spanish, Mandarin, and Vietnamese, as well as more localized dialects like Emirati Arabic, with plans to expand linguistic coverage to nearly all major global languages. The collaboration will also deliver customized regional generative AI agents tailored for cultural alignment and local relevance, enhancing the quality and empathy of patient interactions. The AI agents will be deployed across key specialties such as oncology, cardiology, neurology, and orthopedics, supporting both clinical and administrative tasks to help streamline operations and elevate the patient experience.  

Hippocratic AI, the company that pioneered the first safety-focused generative AI healthcare agents, recently unveiled its patented Polaris 3.0, its most advanced and safety-focused constellation architecture to date. Built on extensive real-world insights from both patients and healthcare providers. With over 1.85 million patient calls and collaborations with more than 25 healthcare enterprise partners, it has set a new benchmark in patient safety and satisfaction, achieving a clinical accuracy rate of 99.38% and a record-high patient experience rating of 8.95 out of 10. At the core of the Polaris constellation system are specialized supervisor models that oversee critical areas such as medications, labs and vitals, nutrition, escalation protocols, and hospital-specific policies. 

Mr. Munjal Shah, Co-Founder and CEO of Hippocratic AI, said, “We’re proud to partner with Burjeel Holdings, one of the most respected healthcare systems in the region. This partnership supports our shared mission of achieving healthcare abundance. Our empathic genAI agents are designed to create a more compassionate and effective patient experience. Together, we will tailor our solutions to meet the specific needs of the communities we serve.” 

The partnership focuses on expanding the deployment of these genAI healthcare agents across Burjeel Holdings' facilities, ensuring that healthcare providers can access the latest advancements in technology and patient support. Incorporating AI technologies into the complex care environment aligns with Burjeel Holdings' commitment to transforming healthcare delivery across critical areas. 

Mr. John Sunil, Group CEO of Burjeel Holdings, said, "At Burjeel Holdings, we believe that the future of healthcare lies in the perfect harmony between cutting-edge technology and personalized care. Our partnership with Hippocratic AI is a testament to our ongoing mission to leverage AI to improve patient experience, efficiency, reduce wait times, and ultimately provide better health outcomes for our patients."  

This collaboration reflects a shared vision: harnessing safety-focused generative AI to support healthcare systems, ease staffing challenges, and deliver hyper personalized, compassionate care - advancing the collective goal of healthcare abundance. 

• Located within Burjeel Cancer Institute (BCI) at Burjeel Medical City, MBZ, this women-led center is designed as a comprehensive, one-stop destination offering dedicated care under one roof 
• The center emphasizes a patient-centered approach, where same-day appointments are offered, ensuring a diagnosis is provided during the patient’s consultation 

Abu Dhabi, April 21, 2025: Burjeel Cancer Institute (BCI), one of the largest cancer care networks in the UAE, has officially launched Burjeel Breast Center, a first-of-its-kind facility offering comprehensive, multidisciplinary care for women with both malignant and benign breast conditions.  

The Center was launched at a ceremony held in BMC in the presence of Dr. Rashed Obaid AlSuwaidi, Director General Abu Dhabi Public Health Center, H.E. Dr. Fayeza Saif Alyafei, Executive Director of the Healthcare Quality Sector, Department of Health – Abu Dhabi, and Mr. Muhammed Shihabuddin, Group Chief Financial Officer, Burjeel Holdings.  

Located within Burjeel Medical City, the center is designed as a one-stop destination for breast health, integrating advanced diagnostics, personalized treatment, and dedicated support services under one roof. The facility has been designed to offer a seamless breast cancer screening experience—from initial screening to diagnosis and treatment—while reducing anxiety and streamlining the journey to recovery. According to experts, with early diagnosis, breast cancer recovery rates can exceed 95%, making timely intervention critical. The center emphasizes a patient-centered approach, where same-day appointments are offered, ensuring a diagnosis is provided during the patient’s consultation. 

At the heart of the center is a women-led medical team, composed of internationally recognized experts in breast health, including Dr. Nehad Abdul Razzaq Kazim Albastaki Consultant Breast Imaging & Interventional Radiologist, an expert Emirati female doctor specializing in radiology and mammography. This all-female team ensures the highest levels of privacy, comfort, and individualized care for patients. Additionally, a special team specializing in breast reconstruction is available for cases requiring surgery and resection, further enhancing the care provided. At the center, samples are processed and delivered on the same day, ensuring a swift and accurate diagnosis.   

Equipped with cutting-edge technology, including HOLOGIC’s 3Dimensions™ Mammography System, the center offers enhanced imaging for early and accurate detection of breast abnormalities. Additionally, the AI-driven breast radiology system assists radiologists in interpreting mammograms, ultrasounds, and MRIs, ensuring accuracy and reducing the chances of false diagnoses. As part of its comprehensive approach, the center also offers a survivorship program, empowering cancer survivors with the tools, support, and care they need to thrive post-treatment.   

Burjeel Breast Center is launching the first-of-its-kind initiative, the “Survivorship Lounge,” which is dedicated to empowering breast cancer survivors by providing a safe, supportive, and informative space focused on life after treatment. This lounge will offer personalized survivorship care plans, wellness resources, psychological support, lifestyle guidance, and education on long-term health—ensuring that every survivor feels seen, supported, and strengthened throughout their post-treatment journey with dedicated team from physicians, psychologists & breastfeeding cancer survivors volunteers. 

“Burjeel Breast Center reimagines the breast care journey by offering an empathetic, data-driven, and efficient clinical environment. By removing barriers to early detection—such as long wait times and the need for prior appointments—we are empowering women to take charge of their health. Early intervention is key, and our walk-in model ensures no time is lost. To enhance patient experience, we have integrated artificial intelligence into our workflow. The AI system can analyze patients’ genetic and hereditary data, helping determine the most effective treatments based on each patient’s unique characteristics,” said Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute.  

Burjeel Cancer Institute Pharmacy Launched 

Enhancing its holistic approach, Burjeel Cancer Institute (BCI) is also launching Burjeel Cancer Institute Pharmacy. Burjeel Cancer Institute Pharmacy proudly holds the distinction of being the first dedicated cancer pharmacy in the UAE. This specialized pharmacy is designed to cater exclusively to the needs of oncology patients, ensuring they have access to a comprehensive range of medications tailored to enhance their quality of life.  

By focusing specifically on cancer care, the pharmacy aims to provide personalized services, expert advice, and support for patients undergoing treatment. This initiative reflects Burjeel Cancer Institute’s commitment to improving the overall patient journey by ensuring access to essential medicines and resources that can aid in their treatment and recovery. 

“The launch of Burjeel Breast Center reflects our commitment to raising the standard of women’s healthcare in the region. By integrating diagnostics, expert consultation, and treatment into one cohesive space, we are delivering a seamless and supportive experience for patients,” said John Sunil, Group CEO of Burjeel Holdings.  

The establishment of Burjeel Breast Center reinforces BCI’s mission to lead in complex cancer care, setting new benchmarks in clinical excellence and innovation across the UAE and the region. 

• Point-of-Care Production Spearheaded by Burjeel Holdings and Caring Cross Promises Affordable, Accessible CAR-T Therapies for Patients in the MENA and Beyond  
• The Collaboration was Announced at Abu Dhabi Global Health Week 

Abu Dhabi, April 15, 2025: In a groundbreaking move set to transform cancer treatment access across MENA, Burjeel Holdings has partnered with U.S.-based non-profit Caring Cross to locally manufacture CAR-T cell therapies at up to 90% less than current international costs. Caring Cross will support Burjeel Holdings with the necessary technology, materials, and specialized training to establish a local ecosystem for manufacturing CAR-T therapies, as well as providing lentiviral vectors essential for clinical development. The collaboration was announced at Abu Dhabi Global Health Week in the presence of Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings.   

CAR-T therapies, which reprogram a patient’s immune cells to attack cancer cells, have shown remarkable success in treating certain blood cancers like leukemia and lymphoma. However, with costs ranging from US$350,000 to over $1 million in global markets, access remains severely restricted. The partnership seeks to dismantle this barrier by enabling the production of CAR-T therapies at a fraction of the current price, making these treatments accessible to a vastly broader patient population in MENA and beyond. 

Enhancing Access to Life-Saving Cancer Care 

The collaboration will position Burjeel Holdings as a regional hub for advanced cell and gene therapies. By enabling local, point-of-care production of patient-specific therapies, the initiative will expand the reach of these therapies to underserved populations across the MENA region. The first phase of the program will focus on CAR-T therapies for leukemia and lymphoma, with plans to explore treatments for other diseases, including HIV, in the future. 

“We are honored to partner with Caring Cross, whose expertise in CAR-T cell therapy production technology will enable us to provide affordable, life-saving treatments to our communities and beyond. This partnership is a pivotal step in our commitment to advancing medical innovation and expanding access to critical healthcare services,” said John Sunil, Group CEO of Burjeel Holdings. 

“We are excited to partner with Burjeel Holdings to improve access to CAR-T cell and other ATMPs for patients across their hospital networks in the MENA region,” said Boro Dropulić, Executive Director of Caring Cross. “This collaboration advances our mission to make these groundbreaking treatments accessible and affordable around the world. By combining our innovative technologies with Burjeel Holdings hospital network and infrastructure, we intend to significantly improve patient access with a sustainable and cost-effective model.” 

Building Local Capabilities and Expanding Impact 

This initiative reflects Burjeel Holdings’ broader mission to expand access to high-quality healthcare in regions that need it most. The partnership will focus on training and developing local healthcare providers, ensuring the sustainable and scalable delivery of CAR-T therapies across MENA, India, and globally.  

“Our collaboration is operating at the cutting edge of medical innovation, opening doors to biological therapies not just in MENA, but also in emerging markets like India and other parts of Asia. This is a monumental stride in enhancing access to cancer treatments and addressing the escalating need for advanced healthcare globally,” said Dr. Ajlan Al Zaki, Director of the Hematology Oncology & Cellular Therapy Center at Burjeel Hospital Abu Dhabi. 

This partnership reinforces Burjeel Holdings’ commitment to transforming the healthcare landscape in MENA and beyond, offering hope and tangible solutions to millions of patients who previously lacked access to life-saving treatments. 

• Acquires 80% stake in Dubai-based Advanced Care Oncology Center  
• Announces plan to launch ACOC-branded radiation oncology centers across GCC 

Abu Dhabi, UAE, February 18, 2025: Burjeel Holdings PLC (“Burjeel” or “the Group”), a leading super-specialty healthcare provider in the MENA region, listed on the Abu Dhabi Securities Exchange (SYMBOL: BURJEEL; ISIN: AEE01119B224), has announced its plan to establish the leading radiation oncology network in the GCC, following its successful acquisition of an 80% stake in the Dubai-based Advanced Care Oncology Center (ACOC), renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy services.This transformative initiative aims to redefine cancer care delivery in the region, leveraging ACOC’s expertise to build a network that ensures accessible and advanced oncology treatment. 

Oncology Global & GCC Landscape 

Globally, cancer cases are projected to increase significantly, driven by aging populations and lifestyle changes. According to the World Health Organization, annual global cancer diagnoses are expected to rise from 20 million in 2024 to over 30 million by 2040, highlighting the growing global burden of cancer. 

In the GCC, the oncology landscape presents both challenges and opportunities. Cancer cases in the region are anticipated to grow by approximately 50% over the next two decades, driven by similar demographic and lifestyle trends. However, the region faces a critical shortage of cancer care infrastructure to manage the growing cases, leading to substantial unmet demand for specialized oncology services. This highlights the immense potential for Burjeel Holdings to expand its oncology platform, ensuring timely and effective cancer treatments to meet regional healthcare needs. 

Additionally, the growing adoption of advanced oncology solutions, such as radiation therapy, robotic surgical oncology, and precision medicine, demonstrates a clear trend towards innovative and specialized care pathways in the GCC. 

Driving Cancer Care Leadership in the GCC 

The planned ACOC-branded network aims to strategically improve oncology access  in underserved markets across the GCC.  

• Enhance Accessibility: The stand-alone ACOC centers will serve as trusted hubs for radiation therapy, expanding patient access to specialized care in underserved regions across the UAE and the GCC. 
• Integrate Advanced Technology: Each center will be equipped with cutting-edge technologies, including state-of-the-art LINAC systems, AI-driven radiation planning, and precision imaging tools.  
• Streamline Referrals: By offering focused and dedicated radiation therapy services, ACOC-branded centers will establish a robust platform for referrals from a broad network of healthcare providers. 
• Support Burjeel Cancer Institute: The network will support Burjeel Cancer Institute (BCI), the Group’s hub for advanced cancer treatments. Patients requiring surgical oncology, immunotherapy, robotic surgery, and bone marrow transplants will benefit from a smooth and integrated transition to the Group’s comprehensive, cutting-edge care. 
• Foster Research & Innovation: Leveraging the Oracle Health EMR implementation for its diverse patient base, the network will drive medical research and data-driven innovations, further solidifying Burjeel’s leadership in preventive oncology and precision medicine. 

Further information, including details of the expansion plan, will be disclosed in due course. 

Burjeel Cancer Institute: Anchor of Burjeel’s Oncology Platform 

This acquisition is a strategic fit for the Group’s growing oncology platform, anchored by BCI,  one of the UAE’s largest cancer care networks. With facilities spanning Abu Dhabi, Al Ain, Al Dhafra, Sharjah, and Dubai, the Group delivers integrated and comprehensive oncology services. These include medical oncology, radiation therapy, robotic surgical oncology, bone marrow transplants, and palliative care. The integration of ACOC into Burjeel’s ecosystem will enhance synergy between stand-alone radiation oncology centers. This structure ensures a streamlined and efficient care pathway, where referrals to the Group are directed toward highly specialized treatments, complementing the network’s broader accessibility and outreach.    

Mr. John Sunil, Group CEO of Burjeel Holdings, said: “Our vision is to establish a comprehensive and advanced oncology network in the GCC, addressing unmet needs in specialized cancer care. By building on ACOC’s legacy of excellence, we will bring accessible, high-quality radiation oncology services closer to patients, significantly enhancing cancer care outcomes across the region. This network will not only support early intervention and treatment but will also connect seamlessly with the Burjeel Cancer Institute for advanced therapies.” 

ACOC Transaction Highlights 

• Value Transaction: Burjeel has acquired an 80% equity stake in ACOC for AED 92 million on a cash-free, debt-free basis, with an option to acquire the remaining stake. ACOC recorded revenue of AED 64 million in 2024. 
• Continuity of Leadership: ACOC’s Founder and CEO, Bashir Abou Reslan, retains a 10% stake and continues to lead the center’s operations, ensuring continuity and excellence in patient care. The remaining 10% continues to be held by Raphael Khlat Middle East FZCO, an existing shareholder. 

About Burjeel Holdings  

Founded in 2007, Burjeel Holdings is a leading super-specialty healthcare services provider in the UAE and Oman, and it operates a growing specialized healthcare segment in Saudi Arabia. The Group operates an integrated and multi-brand healthcare ecosystem across primary, secondary, tertiary, and quaternary medical care, ensuring complex care delivery to patients across all socioeconomic groups. Its network comprises 100 assets across the UAE, Oman, and Saudi Arabia, including 19 hospitals, 29 medical centers, 29 physiotherapy and wellness centers, 15 pharmacies, and other allied services. Burjeel Holdings’ brands include Burjeel, Medeor, LLH, Lifecare, PhysioTherabia and Tajmeel. 

About Advanced Care Oncology Center 

Established in 2017, ACOC is a trusted provider of integrated cancer care services in Dubai. The center is renowned for its specialized expertise in radiation therapy, nuclear medicine, and chemotherapy services. ACOC’s commitment to clinical excellence is underscored by its accreditations, including the Gold Accreditation from Accreditation Canada, awarded in August 2021. It is the only facility in the UAE to hold PET/CT EARL Accreditation from the European Association of Nuclear Medicine (EANM). Additionally, ACOC received the Certificate of Medical Prescription Audit from Bienzobas in Spain in October 2021, demonstrating compliance with European regulatory standards such as EMA guidelines and international protocols from NICE and NCCN. 

Contacts